Comparing SeaStar Medical (NASDAQ:ICU) & PROCEPT BioRobotics (NASDAQ:PRCT)

SeaStar Medical (NASDAQ:ICU) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Earnings and Valuation

This table compares SeaStar Medical and PROCEPT BioRobotics’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SeaStar Medical	N/A	N/A	-$23.01 million	N/A	N/A
PROCEPT BioRobotics	$136.19 million	19.38	-$105.90 million	($2.24)	-23.12

SeaStar Medical has higher earnings, but lower revenue than PROCEPT BioRobotics.

Volatility & Risk

SeaStar Medical has a beta of -1.18, suggesting that its share price is 218% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for SeaStar Medical and PROCEPT BioRobotics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SeaStar Medical	0	0	1	0	3.00
PROCEPT BioRobotics	0	0	6	0	3.00

SeaStar Medical presently has a consensus target price of $5.00, suggesting a potential upside of 614.90%. PROCEPT BioRobotics has a consensus target price of $45.60, suggesting a potential downside of 11.95%. Given SeaStar Medical’s higher probable upside, equities research analysts clearly believe SeaStar Medical is more favorable than PROCEPT BioRobotics.

Institutional and Insider Ownership

1.7% of SeaStar Medical shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 4.5% of SeaStar Medical shares are owned by insiders. Comparatively, 19.6% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares SeaStar Medical and PROCEPT BioRobotics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SeaStar Medical	N/A	N/A	-961.93%
PROCEPT BioRobotics	-77.75%	-46.59%	-30.63%

Summary

PROCEPT BioRobotics beats SeaStar Medical on 6 of the 10 factors compared between the two stocks.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. SeaStar Medical Holding Corporation is headquartered in Denver, Colorado.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.